A grid whose arithmetic holds
Each drug gets a month-to-month rate, a three-month rate with a prepaid total, and a six-month rate with a prepaid total. Every stated saving is the difference between the discounted rate and the standing rate multiplied by the term, and all four of them reconcile.
That sounds like a low bar. It is not: this roster is full of advertised savings that do not reconcile against the seller's own published figures, and checking them is how several of the errors recorded across this site were found.
The page also states, in its own words, that every plan is billed monthly and that a large sum is not taken upfront, while offering a prepayment as an option. Both are true of the grid as published.
A second structure the first one does not mention
Further down the same page, two tiers appear: one described as pay-as-needed with a first-month figure, and one described as a monthly membership. Both carry a shipping and supply fee and both offer laboratory tests at a stated price.
Nothing on the page says whether the membership is required to reach the grid rates, whether the two structures are alternatives, or whether one supersedes the other. Because the seller states two incompatible things and reconciles neither, we have recorded the membership position as unstated and put both structures in the qualifier.
We have separately recorded the shipping and supply fee as a fee row that does not cover medication, so no total on this site can add it to a drug price.
Two first months, and a per-day headline
The pricing page gives each drug a first-month figure at exactly half the standing rate, reached with a discount code. The treatment page gives each drug a different, lower first-month figure with no code attached.
The treatment page also leads with a per-day figure. A per-day headline is not a monthly price and cannot be multiplied into one without knowing the billing cycle; here it is simply the first-month figure divided by thirty.
The privacy policy names the operating limited liability company. No pharmacy is named, no clinician is named, and no service area is published.
Green Cap Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $179/mothe standing month-to-month rate; the same grid prices a three-month term at $149 a month (or $429 prepaid) and a six-month term at $129 a month (or $699 prepaid), and every stated saving reconciles against this figure | September 2026source |
| Tirzepatide (compounded) | $279/mothe standing month-to-month rate; three-month $249 a month (or $629 prepaid), six-month $199 a month (or $999 prepaid). The page states outright that tirzepatide is priced above semaglutide at every tier | September 2026source |
| Glp-1 (compounded) | $25a shipping and supply fee listed on both tiers of the older pricing table on the same page; a fee, not a medication price | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Green Cap Health's current price →Good fit if
- Buyers comparing three plan terms with the prepaid totals published.
- Readers who check a seller's advertised savings against its own rates; these hold.
- People who want the standing rate printed beside every promotional one.
Look elsewhere if
- Anyone who needs to know whether a membership applies; the page carries two answers.
- Buyers comparing first-month figures, which differ between the seller's own two pages.
- Readers who want the pharmacy named.
- People who need a published service area.
How this review was verified
- Read the pricing page and the weight-loss treatment page on 6 September 2026, with a nonsense-path control on the host in the same run.
- Checked every advertised saving against the seller's own standing rate and its own prepaid total; all of them reconcile.
- Separated the GLP-1 tiers from the add-on products priced on the same page, so no unrelated figure was recorded as a GLP-1 rate.
- Recorded both pricing structures in the membership qualifier rather than choosing the one that reads better.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.